Drugging the p53 pathway: understanding the route to clinical efficacy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53 gene is the most frequently mutated gene in human cancers, affecting over half of all tumors.
• Restoring the p53 pathway is a key therapeutic strategy in oncology.
• Inhibitors of MDM2, a negative regulator of p53, have entered clinical trials.

Purpose of the Study:

• To review the current status of p53 pathway modulators.
• To identify emerging therapeutic targets within the p53 pathway.
• To discuss novel drug discovery approaches for targeting protein-protein interactions and mutant p53.

Main Methods:

• Review of current literature on p53 pathway modulators.
• Analysis of emerging therapeutic targets.
• Discussion of challenges and innovations in drug discovery for p53.

Main Results:

• p53 pathway modulators are in clinical development.
• MDM2 inhibitors demonstrate efficacy but reveal on-target toxicities.
• New targets and drug discovery strategies are emerging.

Conclusions:

• Targeting the p53 pathway is a promising cancer therapy strategy.
• Overcoming on-target toxicities and targeting protein-protein interactions are key challenges.
• Innovative approaches are crucial for successful p53-targeted drug discovery.